NeuralRegen is developing innovative treatments to provide Parkinson’s sufferers with improved strength, balance, and movement.
About NeuralRegen
Neurodegenerative Disorders
Neurodegenerative disorders that include Alzheimer’s and Parkinson’s diseases are the leading cause of disability and reduced quality of life with more than 11 million deaths annually. Both are growing rapidly. NueralRegen’s research focuses on biomarker detection, disease monitoring, and next-generation immune-based therapeutics.”
We are fighting to reduce a growing and significant disease burden for patients, families, and providers.
Our approach
We're creating a pharmaceutical derived from colostrum—the nutrient-rich milk produced by cows in the first two weeks after giving birth. This natural source contains tiny biological packages called extracellular vesicles (EVs) that have powerful healing properties.
Our Product
Pharmaceutical (Prescription)
Our prescription medication enhances the EVs with specific therapeutic molecules (microRNAs) designed to target motor skills, cognitive function, and coordination—addressing the core challenges of Parkinson's disease.
Why This Matters
-
Safe and Natural
Derived from a natural source.
-
Affordable
High-yield production keeps costs down
-
Scalable
Strong partnerships with Nebraska's dairy farming community ensure a reliable supply of colostrum
-
Broader Potential
While we're focused on Parkinson's, this approach may address other neurological conditions, including Alzheimer's, ALS, stroke, and multiple sclerosis
built on strong Relationships
Our Nebraska Advantage
Based in the center of the heartland, we've built strong relationships with local farmers who provide the colostrum needed for production. This gives us a sustainable, cost-effective, reliable supply chain located near our laboratories.
-
Built on Evidence
Explore the research, data, and scientific framework supporting our regenerative successes.
-
Led by Excellence
Meet NeuralRegen’s leaders who are shaping the future of neuroregeneration.